328 related articles for article (PubMed ID: 16932687)
1. Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis.
Henderson C; Davis JC
Nat Clin Pract Rheumatol; 2006 Apr; 2(4):211-8. PubMed ID: 16932687
[TBL] [Abstract][Full Text] [Related]
2. Ankylosing spondylitis: new treatment modalities.
Brandt J; Marzo-Ortega H; Emery P
Best Pract Res Clin Rheumatol; 2006 Jun; 20(3):559-70. PubMed ID: 16777582
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic approaches for spondyloarthritis.
Manadan AM; James N; Block JA
Curr Opin Rheumatol; 2007 May; 19(3):259-64. PubMed ID: 17414952
[TBL] [Abstract][Full Text] [Related]
4. Anti-TNF-alpha therapy in ankylosing spondylitis.
De Keyser F; Van den Bosch F; Mielants H
Cytokine; 2006 Mar; 33(5):294-8. PubMed ID: 16516484
[TBL] [Abstract][Full Text] [Related]
5. Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor alpha blockade.
Paul S; Keat A
Rheumatology (Oxford); 2005 Jan; 44(1):17-23. PubMed ID: 15328421
[No Abstract] [Full Text] [Related]
6. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
Rudwaleit M; Schwarzlose S; Hilgert ES; Listing J; Braun J; Sieper J
Ann Rheum Dis; 2008 Sep; 67(9):1276-81. PubMed ID: 18006539
[TBL] [Abstract][Full Text] [Related]
7. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.
Kavanaugh A; Tutuncu Z; Catalan-Sanchez T
Curr Opin Rheumatol; 2006 Jul; 18(4):347-53. PubMed ID: 16763453
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of incentive spirometer exercise on pulmonary functions of patients with ankylosing spondylitis stabilized by tumor necrosis factor inhibitor therapy.
So MW; Heo HM; Koo BS; Kim YG; Lee CK; Yoo B
J Rheumatol; 2012 Sep; 39(9):1854-8. PubMed ID: 22859343
[TBL] [Abstract][Full Text] [Related]
9. [The role of biologic agents in the therapy of ankylosing spondylitis].
Géher P; Nagy MB; Péntek M; Tóth E; Brodszky V; Gulácsi L
Orv Hetil; 2006 Jul; 147(26):1203-13. PubMed ID: 16898082
[TBL] [Abstract][Full Text] [Related]
10. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
[TBL] [Abstract][Full Text] [Related]
11. Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis.
Davis JC
Semin Arthritis Rheum; 2005 Feb; 34(4):668-77. PubMed ID: 15692960
[TBL] [Abstract][Full Text] [Related]
12. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
[No Abstract] [Full Text] [Related]
13. The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis.
Kang KY; Ju JH; Park SH; Kim HY
Rheumatology (Oxford); 2013 Apr; 52(4):718-26. PubMed ID: 23275389
[TBL] [Abstract][Full Text] [Related]
14. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept].
Breedveld FC
Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2273-7. PubMed ID: 16240851
[TBL] [Abstract][Full Text] [Related]
15. [Current therapy with TNFalpha blocking agents for ankylosing spondylitis and undifferentiated spondyloarthritis].
Brandt J; Sieper J; Braun J
Z Rheumatol; 2004 Jun; 63(3):203-10. PubMed ID: 15224223
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF-alpha therapy for ankylosing spondylitis--a specific or nonspecific treatment?
Dayer JM; Krane SM
N Engl J Med; 2002 May; 346(18):1399-400. PubMed ID: 11986415
[No Abstract] [Full Text] [Related]
17. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
Lie E; Kristensen LE; Forsblad-d'Elia H; Zverkova-Sandström T; Askling J; Jacobsson LT;
Ann Rheum Dis; 2015 Jun; 74(6):970-8. PubMed ID: 25710471
[TBL] [Abstract][Full Text] [Related]
18. [Anti-TNF alfa therapy in ankylosing spondylitis].
Cravo AR; Tavares V; Da Silva JC
Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
[TBL] [Abstract][Full Text] [Related]
19. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis.
Coates LC; Cawkwell LS; Ng NW; Bennett AN; Bryer DJ; Fraser AD; Emery P; Marzo-Ortega H
Rheumatology (Oxford); 2008 Jun; 47(6):897-900. PubMed ID: 18403400
[TBL] [Abstract][Full Text] [Related]
20. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
